Allakos Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos or view top-rated stocks.

Wall Street analysts have given Allakos a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allakos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Allakos saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,510,000 shares, a decrease of 15.8% from the December 31st total of 4,170,000 shares. Based on an average trading volume of 325,400 shares, the days-to-cover ratio is currently 10.8 days. Currently, 11.3% of the company's stock are sold short.
View Allakos' Short Interest.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Allakos.

Allakos Inc. (NASDAQ:ALLK) issued its earnings results on Sunday, February, 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.02.
View Allakos' earnings history.

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALLK stock has increased by 91.0% and is now trading at $111.38.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12-month target prices for Allakos' shares. Their forecasts range from $145.00 to $218.00. On average, they expect Allakos' share price to reach $181.50 in the next year. This suggests a possible upside of 63.0% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Some companies that are related to Allakos include Genmab A/S (GMAB), UCB (UCBJF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Genmab A/S (GNMSF), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), CureVac (CVAC), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).
View all of ALLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.72%), Baker BROS. Advisors LP (1.36%), Alliancebernstein L.P. (0.95%), Northern Trust Corp (0.60%), Norges Bank (0.54%) and Charles Schwab Investment Management Inc. (0.40%). Company insiders that own Allakos stock include Adam Tomasi, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker and Venture Fund (Ohi Rivervest II.
View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Candriam Luxembourg S.C.A., Alliancebernstein L.P., SG Americas Securities LLC, Aviva PLC, Jane Street Group LLC, ClariVest Asset Management LLC, and State of Wisconsin Investment Board. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, and Paul Edward Walker.
View insider buying and selling activity for Allakos or view top insider-selling stocks.

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Voloridge Investment Management LLC, Charles Schwab Investment Management Inc., Northern Trust Corp, Baker BROS. Advisors LP, Federated Hermes Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for Allakos or or view top insider-buying stocks.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $111.38.

Allakos has a market capitalization of $5.85 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

Allakos employs 114 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]